Sangamo Biosciences (SGMO) Tops Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Piper Jaffray Remains Sidelined on Sangamo Biosciences (SGMO) Following 4Q Report
February 28, 2017 12:01 PM ESTPiper Jaffray reiterated a Neutral rating and $5.00 price target on Sangamo BioSciences (NASDAQ: SGMO) following the company's 4Q earnings report. Sangamo reported 4Q16 revenues of $8.9M, slightly above projections, and opex of $18.8M, slightly below projections.
Analyst Charles Duncan commented, "Today Sangamo reported 4Q16 financial... More
